Loading...
  • Obsessive Compulsi
  • Paradoxical worsening of obsessive-compulsive disorder or serotonin syndrome has been reported. (drugs.com)
  • For these reasons, SSRIs are the first-line pharmacological approach in patients with anxiety disorders, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). (pulsetoday.co.uk)
  • Following are select findings from feasibility studies performed at three sites in the United States and one site in Europe, demonstrating the probable benefit of Reclaim TM DBS Therapy for OCD * in treating obsessive-compulsive disorder. (medtronic.com)
  • At baseline, 100% (26/26) of the patients enrolled into the study protocols at the 4 collaborating centers met the criterion for "severe" OCD (YBOCS score of 30 or greater) as defined by the Expert Consensus Panel on obsessive-compulsive disorder (1997). (medtronic.com)
  • adjunctive treatment
  • The device was approved for use in conjunction with drugs or surgery "…as an adjunctive treatment of adults and adolescents over 12 years of age with medically refractory partial onset seizures. (unicare.com)
  • adults
  • Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). (clinicaltrials.gov)
  • Risks of pathological mood elevation may be greater in association with treatment with older tricyclic ADs than with modern, second-generation agents in adults [ 3 , 9 , 12 ], but serotonin reuptake inhibitors have been implicated at ages below mid-adolescence [ 4 , 13 , 14 ]. (karger.com)
  • These risks need to be balanced against evidence that the responsiveness of depression to AD treatment may be less in juveniles (and rarely studied separately in children) compared to adults [ 3 , 15 , 16 , 17 ]. (karger.com)
  • In addition, the use of ADs to treat a broad range of disorders has increased several-fold in both adults and children following the introduction of modern ADs since the late 1980s, even for patients with known or suspected BPD [ 18 , 19 ]. (karger.com)
  • Earlier this month, the U.S. Food and Drug Administration approved Spravato, an esketamine nasal spray, for treating depression in adults with treatment-resistant depression in conjunction with an oral antidepressant. (viachristi.org)
  • dose
  • It is typically available in 15 mg tablets and doses usually range from 30-90 mg per day, with 15 mg every day or every other day suggested as a maintenance dose following a successful course of treatment. (wikipedia.org)
  • anorexia nervosa
  • This study aims to explore the thinking styles in women who have recovered from anorexia nervosa compared to women who have never had any eating disorder. (nedic.ca)
  • The study is open to female participants between the ages of 18-65 who have either no history of a previous eating disorder, or who have a past history of Anorexia Nervosa. (nedic.ca)
  • recurrent
  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by mutations in the NOTCH3 gene on chromosome (19p13.2-p13.1), is a rare monogenic disorder known to cause recurrent transient ischemic attacks, strokes, and migraines (with or without aura). (dovepress.com)
  • Drug treatment is recommended for patients who are at risk for recurrent depression. (limamemorial.org)
  • therapies
  • The benefits of CBT may occur more quickly, but those of short-term psychodynamic therapies may continue to increase after treatment. (rcpsych.org)
  • onset
  • In April 1999, the Centers for Medicare and Medicaid Services (CMS) issued a national coverage determination (NCD 160.18) for implantable VNS as an effective treatment for medically refractory partial onset seizures when surgery is not recommended or has failed. (unicare.com)
  • In preclinical studies, GLYX-13 has shown promising signs of robust antidepressant activity with excellent safety, demonstrating rapid onset of effect and long duration after a single administration. (drugs.com)
  • The number of previous depressive episodes, gender, or age at onset did not predict ECT treatment outcome. (hindawi.com)
  • medication
  • It remains controversial whether increased risk of suicide is due to the medication (a paradoxical effect) or part of the depression itself (i.e. the antidepressant enables those who are severely depressed - who ordinarily would be paralyzed by their depression - to become more alert and act out suicidal urges before fully recovered from their depressive episode). (over.net)
  • Until today, there has been no approved medication for treatment-resistant depression. (bio-medicine.org)
  • A treatment approach that focuses exclusively on one of these factors is not likely to be as beneficial as a treatment approach that addresses both psychological and biological aspects (through, for example, psychotherapy and medication). (psychcentral.com)
  • A meta-analysis of Haq and colleagues revealed that longer depressive episodes and medication failure at baseline are reliable predictors of poor ECT response. (hindawi.com)
  • Other studies reported higher rates of remission in elderly patients, though it still remains unclear whether age could be a useful predictor independent of medication failure and duration of the current depressive episode [ 2 ]. (hindawi.com)
  • double-blind
  • This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. (clinicaltrials.gov)
  • A safety follow-up contact (visit or phone call) was made 4 weeks after completion of the 8-week double-blind treatment period (2 weeks after the end of the 2-week discontinuation period). (clinicaltrials.gov)
  • When judged by the narrow criterion of the availability of sufficient numbers of high-quality double-blind random allocation controlled trials and meta-analyses, it may be fair to conclude that the evidence base for the most used treatments for depression is weak. (rcpsych.org)
  • The study will include four parts: a 2 week Screening part, a 4 week run-in part, an 8 week double-blind treatment part, and a 52 week Open-Label Extension part. (clinicaltrials.gov)
  • Subjects who have successfully completed the Enrichment Run-in part will enter the Double- Blind treatment part of the study per below: NaBen® treated subjects: Subjects will continue receiving NaBen® for another 8 weeks. (clinicaltrials.gov)
  • rTMS
  • Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resista. (nih.gov)
  • Previous studies have shown effectiveness of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. (nih.gov)